EMBC at a glance
Embecta Corp. (EMBC, SEC CIK 1872789) filed its latest 10-K annual report on November 25, 2025, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 7, 2026 and Form 4 insider filings as recently as September 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended September 30, 2025 (FY2025), Embecta Corp. (EMBC) reported revenue of $1.1 billion (down 3.8% from FY2024) and net income of $95.4 million. Diluted EPS was $1.62.
- As of June 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Embecta Corp. (EMBC) shares worth $67.5 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Morris Milton Mayo on September 4, 2026 of 6,293 shares at $5.88 per share.
- In the last 90 days, EMBC insiders reported 4 open-market purchases ($558K) and 1 open-market sale ($37K) on Form 4, a net purchase of $521K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.1B
- −3.8% vs prior year
- Insiders · 90 days
- 4 buys · 1 sell
- Net +$521K
- 13F holders
- 29 funds
- $67.5M · −2 vs prior quarter
- Latest 8-K
- Aug 7, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $271.7M, down 8.1% YoY from $295.5M, driven by $20.1M price and $19.9M volume declines
- Gross margin 56.4% vs 66.7% YoY; operating income $48.7M vs $94.0M
- Owen Mumford contributed $13.8M revenue, partially offsetting legacy portfolio declines
- Owen Mumford acquisition for $169.9M upfront cash; $8.7M stock repurchases and dividend reduced to $0.01 per share
- Headwinds from tariffs, supply-chain costs, pricing pressure, and emerging diabetes therapies reducing injection-device demand
Risk Factors
- No material risk-factor changes from the 2025 Form 10-K or March 31, 2026 Form 10-Q
- Revolving commitments reduced from $500 million to $310 million under the August 6, 2026 credit amendment
- $100 million revolving tranche matures March 31, 2027, creating near-term refinancing exposure
- Extended tranche interest spread increased to Term SOFR plus 3.50% from 3.00%
- More restrictive covenants may constrain growth investment and competitive execution
AI summary of the EMBC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q3 revenue $271.7M, down 8.1%, with U.S. revenue down 24.6% despite International growth of 11.5%
- Profitability weakened materially: adjusted operating margin 25.5% versus 36.9%, while adjusted EPS fell to $0.56 from $1.12
Item 2.02: Results of Operations and Financial Condition
- Embecta furnished fiscal Q3 2026 results for the quarter ended June 30, 2026
- Detailed financial results and management commentary are contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Owen Mumford’s FY2025 financials support Embecta’s Rule 3-05 acquisition reporting following the May 15, 2026 acquisition
- Revenue £68.6M and net income £1.7M, but operating loss £825K before a £2.1M fixed-asset sale gain
Item 7.01: Regulation FD Disclosure
- Embecta announced completion of the Transaction on May 15, 2026
- Exhibit 99.1 contains the transaction details and represents the primary investor reference
Item 2.01: Completion of Acquisition or Disposition of Assets
- Completion of Owen Mumford Holdings acquisition under March 19, 2026 sale-and-purchase agreement
- Owen Mumford transaction marks strategic expansion of Embecta’s medical-device portfolio
AI summaries of EMBC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for EMBC
Don't miss the next EMBC filing
- Alerts as it files. A push when EMBC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut EMBC, by share count.
- Ask anything. An AI agent that reads every EMBC filing and answers with sources.
EMBC alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Morris Milton Mayo | Sell | Sep 4, 2026 | 6,293 | $5.88 |
| Mann Jeffrey Z | Buy | Aug 12, 2026 | 20,000 | $4.99 |
| Kurdikar Devdatt | Buy | Aug 12, 2026 | 30,000 | $4.70 |
| Elguicze Jacob | Buy | Aug 12, 2026 | 20,000 | $4.67 |
| HOMBACH ROBERT J. | Buy | Aug 12, 2026 | 45,000 | $4.97 |
| Casner Jean | F | Aug 9, 2026 | 1,480 | $4.42 |
| Pomeroy Claire | A | Feb 11, 2026 | 22,841 | - |
| HOMBACH ROBERT J. | A | Feb 11, 2026 | 22,841 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.1B | $1.1B |
| Gross Profit | - | $735.2M | $676.8M |
| Operating Income | - | $166.8M | $242.1M |
| Net Income | - | $78.3M | $95.4M |
| Gross Margin | - | 65.5% | 62.6% |
| Op. Margin | - | 14.9% | 22.4% |
| Net Margin | - | 7.0% | 8.8% |
| Balance Sheet | |||
| Total Assets | $1.2B | $1.3B | $1.1B |
| Equity | -$821.7M | -$738.3M | -$650.6M |
| ROE | - | -10.6% | -14.7% |
| Per Share | |||
| EPS | - | $1.34 | $1.62 |
| Cash Flow | |||
| Operating CF | - | $35.7M | $191.7M |
| CapEx | - | $15.8M | $9.3M |
Source: XBRL data in Embecta Corp. (EMBC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate EMBC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 29 | $67.5M |
| Q1 2026 | 31 | $231.3M |
| Q4 2025 | 30 | $301.3M |
| Q3 2025 | 29 | $370.2M |
| Q2 2025 | 28 | $252.3M |
| Q1 2025 | 26 | $225.4M |
| Q4 2024 | 21 | $366.0M |
| Q3 2024 | 17 | $129.4M |
- Morgan Stanley+1.39M (+227%)
- Ameriprise Financial+1.24M (+155%)
- AQR Capital Management+645.0K (+195%)
- Goldman Sachs Group+413.6K (+55%)
- D.E. Shaw & Co+117.7K (+22%)
- BlackRock−4.57M (-50%)
- State Street Corp−935.3K (-37%)
- Millennium Management−648.2K (-41%)
- Dimensional Fund Advisors−633.5K (-68%)
- Vanguard Portfolio Management LLC−439.6K (-29%)
- Allstate+160.2K
- Raymond James Financial−300.7K
- Renaissance Technologies LLC−144.3K
- Two Sigma Investments−103.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 211 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
EMBC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 8-K | Aug 7, 2026 | - | Analysis | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 31, 2026 | - | Analysis | - |
| 8-K | May 15, 2026 | - | Analysis | |
| SC 13G | May 5, 2026 | - | - | |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| SC 13G | Apr 29, 2026 | - | - | |
| 8-K | Mar 20, 2026 | - | - | - |
| 4 | Feb 13, 2026 | - | - | |
| 8-K | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 10-Q | Feb 5, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Feb 5, 2026 | - | - | |
| 4 | Dec 1, 2025 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
EMBC SEC filings: frequently asked questions
Are EMBC insiders buying or selling?
In the last 90 days, Embecta Corp. (EMBC) officers, directors and 10% owners reported 4 open-market purchases worth $557,945 by 4 insiders and 1 open-market sale worth $36,971 by 1 insider on Form 4, a net purchase of $520,974. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold EMBC stock?
As of June 30, 2026, the largest Embecta Corp. (EMBC) holders among the 13F filers tracked by SignalX were BlackRock ($15.0 million), Vanguard Capital Management LLC ($8.3 million), Ameriprise Financial ($6.6 million), Morgan Stanley ($6.5 million), State Street Corp ($5.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was EMBC's revenue in fiscal year 2025?
For the fiscal year ended September 30, 2025 (FY2025), Embecta Corp. (EMBC) reported revenue of $1.1 billion (down 3.8% from FY2024) and net income of $95.4 million. Diluted EPS was $1.62. The figures come from the XBRL data in the 10-K.
What did EMBC report in its latest 8-K?
Embecta Corp. (EMBC) filed an 8-K on August 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $271.7M, down 8.1%, with U.S. revenue down 24.6% despite International growth of 11.5%.
What are the latest EMBC SEC filings?
Embecta Corp. (EMBC) filed its latest 10-K annual report on November 25, 2025, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 7, 2026 and a Form 4 insider filing on September 8, 2026.
What is EMBC's SEC CIK number?
Embecta Corp. (EMBC)'s SEC Central Index Key (CIK) is 1872789. EDGAR lists every EMBC filing under that number.
Ask anything about EMBC
The research agent reads EMBC's filings, financials, insider trades and 13F holders, then answers with sources.